Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy

Lignende værker

• Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma
  af: Joshua N. Gustine, et al.
  Udgivet: (2025-06-01)
• Impact of body mass index on anti-BCMA chimeric antigen receptor T-cell therapy outcomes in multiple myeloma
  af: Ruth Choa, et al.
  Udgivet: (2025-12-01)
• Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy
  af: Jessica S. Little, et al.
  Udgivet: (2025-08-01)
• Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy
  af: Masooma Shifa Rana, et al.
  Udgivet: (2026-04-01)
• sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
  af: Katja Seipel, et al.
  Udgivet: (2022-03-01)